Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Treasury Shares: 2020-2023

Historic Treasury Shares for Adma Biologics (ADMA) over the last 4 years, with Dec 2023 value amounting to $12.5 million.

  • Adma Biologics' Treasury Shares was N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $12.5 million for FY2023, which is 7.56% down from last year.
  • According to the latest figures from FY2023, Adma Biologics' Treasury Shares is $12.5 million, which was down 7.56% from $13.5 million recorded in FY2022.
  • Over the past 5 years, Adma Biologics' Treasury Shares peaked at $13.5 million during FY2022, and registered a low of $4.5 million during FY2020.
  • Its 3-year average for Treasury Shares is $10.2 million, with a median of $12.5 million in 2023.
  • In the last 5 years, Adma Biologics' Treasury Shares spiked by 198.69% in 2022 and then decreased by 7.56% in 2023.
  • Over the past 4 years, Adma Biologics' Treasury Shares (Yearly) stood at $4.5 million in 2020, then remained steady at $4.5 million in 2021, then surged by 198.69% to $13.5 million in 2022, then decreased by 7.56% to $12.5 million in 2023.